1) 泉孝英編, 藤井勇佑, 栗山健一, ガイドライン外来診療 2017, 日経メディカル開発, 2017, 349–356.
2) 厚生労働省 e-ヘルスネット “不眠症”, https://www.e-healthnet.mhlw.go.jp/information/heart/k-02-001.html. (閲覧日: 2021 年 11 月 3 日)
3) Pase, M. P.; Himali, J. J.; Grima, N. A.; Beiser, A. S.; Satizabal, C. L.; Aparicio, H. J.; Thomas, R. J.; Gottlieb, D. J.; Auerbach, S. H.; Seshadri, S., Sleep architecture and the risk of incident dementia in the community. Neurology. 2017, 89, 1244–1250.
4) von Economo. C., Sleep as a problem of localization. J. Nerv. Ment. Dis. 1930, 71, 249–259.
5) 櫻井武, 睡眠の科学, 講談社, 2010, 78.
6) Sakurai, T., The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat. Rev. Neurosci. 2007, 8, 171–181.
7) Saper, C. B.; Chou, T. C.; Scammell, T. E., The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001, 24, 726–731.
8) 治験薬マニュアル, 医学書院, 2011, 153–175.
9) Nakamura, M.; Ishii, M.; Niwa, Y.; Yamazaki, M.; Ito, H., Temporal changes in postural sway caused by ultrashort-acting hypnotics: triazolam and zolpidem. ORL J. Otorhinolaryngol. Relat. Spec. 2005, 67, 106–112.
10) Brzezinski, A., Melatonin in humans. N. Engl. J. Med. 1997, 336, 186–195.
11) Miyamoto, M., Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci. Ther. 2009, 15, 32–51.
12) Sakurai, T.; Amemiya, A.; Ishii, M.; Matsuzaki, I.; Chemelli, R. M.; Tanaka, H.; Williams, S. C.; Richardson, J. A.; Kozlowski, G. P.; Wilson, S.; Arch, J. R.; Buckingham, R. E.; Haynes, A. C.; Carr, S. A.; Annan, R. S.; McNulty, D. E.; Liu, W. S.; Terrett, J. A.; Elshourbagy, N. A.; Bergsma, D. J.; Yanagisawa, M., Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92, 573–585.
13) de Lecea, L.; Kilduff, T. S.; Peyron, C.; Gao, X.; Foye, P. E.; Danielson, P. E.; Fukuhara, C.; Battenberg, E. L.; Gautvik, V. T.; Bartlett, F. S., 2nd; Frankel, W. N.; van den Pol, A. N.; Bloom, F. E.; Gautvik, K. M.; Sutcliffe, J. G., The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 322–327.
14) Chemelli, R. M.; Willie, J. T.; Sinton, C. M.; Elmquist, J. K.; Scammell, T.; Lee, C.; Richardson, J. A.; Williams, S. C.; Xiong, Y.; Kisanuki, Y.; Fitch, T. E.; Nakazato, M.; Hammer, R. E.; Saper, C. B.; Yanagisawa, M., Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98, 437–451.
15) Willie, J. T.; Chemelli, R. M.; Sinton, C. M.; Tokita, S.; Williams, S. C.; Kisanuki, Y. Y.; Marcus, J. N.; Lee, C.; Elmquist, J. K.; Kohlmeier, K. A.; Leonard, C. S.; Richardson, J. A.; Hammer, R. E.; Yanagisawa, M., Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003, 38, 715–730.
16) Hara, J.; Beuckmann, C. T.; Nambu, T.; Willie, J. T.; Chemelli, R. M.; Sinton, C. M.; Sugiyama, F.; Yagami, K.; Goto, K.; Yanagisawa, M.; Sakurai, T., Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001, 30, 345–354.
17) Lin, L.; Faraco, J.; Li, R.; Kadotani, H.; Rogers, W.; Lin, X.; Qiu, X.; de Jong, P. J.; Nishino, S.; Mignot, E., The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98, 365–376.
18) Peyron, C.; Faraco, J.; Rogers, W.; Ripley, B.; Overeem, S.; Charnay, Y.; Nevsimalova, S.; Aldrich, M.; Reynolds, D.; Albin, R.; Li, R.; Hungs, M.; Pedrazzoli, M.; Padigaru, M.; Kucherlapati, M.; Fan, J.; Maki, R.; Lammers, G. J.; Bouras, C.; Kucherlapati, R.; Nishino, S.; Mignot, E., A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 2000, 6, 991–997.
19) Nishino, S.; Ripley, B.; Overeem, S.; Lammers, G. J.; Mignot, E., Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000, 355, 39–40.
20) Thannickal, T. C.; Moore, R. Y.; Nienhuis, R.; Ramanathan, L.; Gulyani, S.; Aldrich, M.; Cornford, M.; Siegel, J. M., Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27, 469–474.
21) Hagan, J. J.; Leslie, R. A.; Patel, S.; Evans, M. L.; Wattam, T. A.; Holmes, S.; Benham, C. D.; Taylor, S. G.; Routledge, C.; Hemmati, P.; Munton, R. P.; Ashmeade, T. E.; Shah, A. S.; Hatcher, J. P.; Hatcher, P. D.; Jones, D. N.; Smith, M. I.; Piper, D. C.; Hunter, A. J.; Porter, R. A.; Upton, N., Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl. Acad. Sci. U S A 1999, 96, 10911–10916.
22) Nambu, T.; Sakurai, T.; Mizukami, K.; Hosoya, Y.; Yanagisawa, M.; Goto, K., Distribution of orexin neurons in the adult rat brain. Brain Res. 1999, 827, 243–260.
23) Trivedi, P.; Yu, H.; MacNeil, D. J.; Van der Ploeg, L. H.; Guan, X. M., Distribution of orexin receptor mRNA in the rat brain. FEBS Lett. 1998, 438, 71–75.
24) Marcus, J. N.; Aschkenasi, C. J.; Lee, C. E.; Chemelli, R. M.; Saper, C. B.; Yanagisawa, M.; Elmquist, J. K., Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 2001, 435, 6–25.
25) Yamanaka, A.; Tsujino, N.; Funahashi, H.; Honda, K.; Guan, J. L.; Wang, Q. P.; Tominaga, M.; Goto, K.; Shioda, S.; Sakurai, T., Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem. Biophys. Res. Commun. 2002, 290, 1237–1245.
26) Nakamura, T.; Uramura, K.; Nambu, T.; Yada, T.; Goto, K.; Yanagisawa, M.; Sakurai, T., Orexin- induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res. 2000, 873, 181–187.
27) Liu, R. J.; van den Pol, A. N.; Aghajanian, G. K., Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J. Neurosci. 2002, 22, 9453–9464.
28) Brown, R. E.; Sergeeva, O. A.; Eriksson, K. S.; Haas, H. L., Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin/hypocretin, histamine and noradrenaline). J. Neurosci. 2002, 22, 8850–8859.
29) Gotter, A. L.; Webber, A. L.; Coleman, P. J.; Renger, J. J.; Winrow, C. J., International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology. Pharmacol. Rev. 2012, 64, 389–420.
30) Brisbare-Roch, C.; Dingemanse, J.; Koberstein, R.; Hoever, P.; Aissaoui, H.; Flores, S.; Mueller, C.; Nayler, O.; van Gerven, J.; de Haas, S. L.; Hess, P.; Qiu, C.; Buchmann, S.; Scherz, M.; Weller, T.; Fischli, W.; Clozel, M.; Jenck, F., Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 2007, 13, 150–155.
31) Fujimoto, T.; Rikimaru, K.; Fukuda, K.; Sugimoto, H.; Masuda, K.; Ohyabu, N.; Banno, Y.; Tokunaga, N.; Kawamoto, T.; Tomata, Y.; Kumagai, Y.; Iida, M.; Nagano, Y.; Yoneyama-Hirozane, M.; Shimizu, Y.; Sasa, K.; Ishikawa, T.; Yukitake, H.; Ito, M.; Aoyama, K.; Matsumoto, T., Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist. ACS Med. Chem. Lett. 2020, 13, 457–462.
32) Bettica, P.; Squassante, L.; Zamuner, S.; Nucci, G.; Danker-Hopfe, H.; Ratti, E. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 2012, 35, 1097–1104.
33) Cox, C. D.; Breslin, M. J.; Whitman, D. B.; Schreier, J. D.; McGaughey, G. B.; Bogusky, M. J.; Roecker, A. J.; Mercer, S.P.; Bednar, R. A.; Lemaire, W.; Bruno, J. G.; Reiss, D. R.; Harrell, C. M.; Murphy, K. L.; Garson, S. L.; Doran, S. M.; Prueksaritanont, T.; Anderson, W. B.; Tang, C.; Roller, S.; Cabalu, T. D.; Cui, D.; Hartman, G. D.; Young, S. D.; Koblan, K. S.; Winrow, C. J.; Renger, J. J.; Coleman, P. J. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3- benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2- yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J. Med. Chem. 2010, 53, 5320– 5332.
34) Coleman, P.J.; Schreier, J.D.; Cox, C. D; Breslin M. J.; Whitman D. B.; Bogusky M. J.; McGaughey G. B.; Bednar R. A.; Lemaire W.; Doran S. M.; Fox S. V.; Garson S. L.; Gotter A. L.; Harrell C. M.; Reiss D. R.; Cabalu T. D.; Cui D.; Prueksaritanont T.; Stevens J.; Tannenbaum P. L.; Ball R. G.; Stellabott J.; Young S. D.; Hartman G. D.; Winrow C. J.; Renger J. J. Discovery of [(2R,5R)-5- {[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2- yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem 2012, 7, 415–424.
35) Yoshida, Y.; Naoe, Y.; Terauchi, T.; Ozaki, F.; Doko, T.; Takemura, A.; Tanaka, T.; Sorimachi, K.; Beuckmann, C. T.; Suzuki, M.; Ueno, T.; Ozaki, S.; Yonaga, M., Discovery of (1R,2S)-2-{[(2,4- Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2- yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist. J. Med. Chem. 2015, 58, 4648–4664.
36) Muehlan, C.; Brooks, S.; Zuiker, R.; van Gerven, J.; Dingemanse, J., Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration. Eur. Neuropsychopharmacol. 2019, 29, 847–857.
37) Hasegawa, E.; Yanagisawa, M.; Sakurai, T.; Mieda, M., Orexin neurons suppress narcolepsy via 2 distinct efferent pathways. J. Clin. Invest. 2014, 124, 604–616.
38) Bonaventure, P, Shelton, J, Yun, S, Nepomuceno, D, Sutton, S, Aluisio, L, Fraser, I, Lord, B, Shoblock, J, Welty, N, Chaplan, SR, Aguilar, Z, Halter, R, Ndifor, A, Koudriakova, T, Rizzolio, M, Letavic, M, Carruthers, NI, Lovenberg, T, Dugovic, C. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. J. Pharmacol. Exp. Ther. 2015, 354, 471–482.
39) Sharf, R.; Sarhan, M.; Dileone, R. J., Role of orexin/hypocretin in dependence and addiction. Brain Res. 2010, 1314, 130–138.
40) Johnson, P. L.; Samuels, B. C.; Fitz, S. D.; Federici, L. M.; Hammes, N.; Early, M. C.; Truitt, W.; Lowry, C. A.; Shekhar, A., Orexin 1 receptors are a novel target to modulate panic responses and the panic brain network. Physiol. Behav. 2012, 107, 733–742.
41) Citrome, L. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int. J. Clin. Pract. 2014, 68, 1429–1441.
42) デエビゴ錠 2.5 mg・5 mg・10 mg 添付文書 2020 年 1 月作成（ 第 1 版） 【薬物動態】 1． 血中濃度
43) Smith, D. A.; Beaumont, K.; Maurer, T. S.; Di, L., Volume of Distribution in Drug Design. J. Med. Chem. 2015, 58, 5691–5698.
44) Arnott, J. A.; Planey, S. L., The influence of lipophilicity in drug discovery and design. Expert Opin. Drug Discov. 2012, 7, 863–875.
45) Waring, M. J., Lipophilicity in drug discovery. Expert Opin. Drug Discov. 2010, 5, 235–248.
46) Cox, C. D.; McGaughey, G. B.; Bogusky, M. J.; Whitman, D. B.; Ball, R. G.; Winrow, C. J.; Renger, J. J.; Coleman, P. J., Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding. Bioorg. Med. Chem. Lett. 2009, 19, 2997–3001.
47) Molecular Operating Environment (MOE), 2013.08; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2013.
48) Accelrys Software Inc., Discovery Studio Modeling Environment, Release 4.0 San Diego: Accelrys Software Inc., 2013.
49) Ito, S.; Hirata, Y.; Nagatomi, Y.; Satoh, A.; Suzuki, G.; Kimura, T.; Satow, A.; Maehara, S.; Hikichi, H.; Hata, M.; Ohta, H.; Kawamoto, H., Discovery and biological profile of isoindolinone derivatives as novel metabotropic glutamate receptor 1 antagonists: a potential treatment for psychotic disorders. Bioorg. Med. Chem. Lett. 2009, 19, 5310–5313.
50) Hosea, N. A.; Collard, W. T.; Cole, S.; Maurer, T. S.; Fang, R. X.; Jones, H.; Kakar, S. M.; Nakai, Y.; Smith, B. J.; Webster, R.; Beaumont, K., Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J. Clin. Pharmacol. 2009, 49, 513–533.
51) A) Conformations of compounds in water were caluqulated using the replica-exchange molecular dynamics (REMD) simulation implemented in GROMACS 5.0.4.a. For each compound, 8 sets of 20 ns REMD simulation with 8 temperature replicas were carried out to sample sufficient conformational space. Temperatures of replicas were set to 310.0, 350.7, 396.0, 446.6, 503.0, 565.8, 635.9, and 714.0K. GAFF forcefiledb and GBSA modelc are applied to compounds and solvent (water), respectively. a) Hess, B.; Kutzner, C.; van der Spoel, D.; Lindahl, E. J. Chem. Theory Comput. 2008, 4, 435–447. b) Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. J. Comput. Chem. 2004, 25, 1157–1174. c) Onufriev, A.; Case, D. A.; Bashford, D. J. Comput. Chem. 2002, 23, 1297–1304. B) The probability density functions of 5-fluoro-2-pyridyl moiety positions under the alignment of 2-(4-tolyl)-2H-1,2,3-triazole substructures were calculated using the kernel density estimation methodd of sampled conformations. The isosurface indicates the minimal space which 80% of conformations exist. d) R Core Team. R: A language and environment for statistical computing, R Foundation for Statistical Computing: Vienna, Austria, 2015. C) Active U-form conformation was modeled by the crystal structure65 of the human OX2 R bound to suvorexant.
52) A) Rydberg, P, Gloriam, DE, Zaretzki, J, Breneman, C, Olsen, L. SMARTCyp: A 2D Method for Prediction of Cytochrome P450-Mediated Drug Metabolism. ACS Med. Chem. Lett. 2010, 1, 96– 100. B) Rydberg, P, Gloriam, DE, Olsen, L. The SMARTCyp cytochrome P450 metabolism prediction server. Bioinformatics 2010, 26, 2988–2989. C) Rydberg, P, Olsen, L. Ligand-Based Site of Metabolism Prediction for Cytochrome P450 2D6. ACS Med. Chem. Lett. 2012, 3, 69–73. D) Rydberg, P, Olsen, L. Predicting drug metabolism by cytochrome P450 2C9: comparison with the 2D6 and 3A4 isoforms. ChemMedChem 2012, 7, 1202–1209. E) Rydberg, P, Jorgensen, MS, Jacobsen, TA, Jacobsen, AM, Madsen, KG, Olsen, L. Nitrogen inversion barriers affect the N- oxidation of tertiary alkylamines by cytochromes P450. Angew. Chem. Int. Ed. Engl. 2013, 52, 993–997. F) Rydberg, P.; Rostkowski, M.; Gloriam, D. E.; Olsen, L., The contribution of atom accessibility to site of metabolism models for cytochromes P450. Mol. Pharm. 2013, 10, 1216– 1223.
53) Edward H. Kerns, LD, Drug-like properties: concepts, structure design and methods. Elsevier: p 260–270.
54) Mahar Doan, K. M.; Humphreys, J. E.; Webster, L. O.; Wring, S. A.; Shampine, L. J.; Serabjit- Singh, C. J.; Adkison, K. K.; Polli, J. W., Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 2002, 303, 1029–1037.
55) Waring M. J.; Johnstone, C., A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg. Med. Chem. Lett. 2007, 17, 1759–1764.
56) Uchiyama, M.; Kambe, D.; Imadera, Y.; Kajiyama, Y.; Ogo, H.; Uchimura, N., Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double- blind, placebo-controlled phase 2 study. Phychopharmacology 2022. doi: 10.1007/s00213-022- 06089-6. Online ahead of print.
57) Yin, J.; Mobarec, J. C.; Kolb, P.; Rosenbaum, D. M., Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant. Nature 2015, 519, 247–250.
58) Yin, J.; Babaoglu, K.; Brautigam, C. A.; Clark, L.; Shao, Z.; Scheuermann, T. H.; Harrell, C. M.; Gotter, A. L.; Roecker, A. J.; Winrow, C. J.; Renger, J. J.; Coleman, P. J.; Rosenbaum, D. M., Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors. Nat. Struct. Mol. Biol. 2016, 23, 293–299.
59) Hong, C.; Byrne, N. J.; Zamlynny, B.; Tummala, S.; Xiao, L.; Shipman, J. M.; Partridge, A. T.; Minnick, C.; Breslin, M. J.; Rudd, M. T.; Stachel, S. J.; Rada, V. L.; Kern, J. C.; Armacost, K. A.; Hollingsworth, S. A.; O'Brien J. A.; Hall, D. L.; McDonald, T. P.; Strickland C.; Brooun, A.; Soisson, S. M.; Hollenstein, K., Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation. Nat. Commun. 2021, 12, 815.
60) Malherbe, P.; Roche, O.; Marcuz, A.; Kratzeisen, C.; Wettstein, J. G.; Bissantz, C., Mapping the Binding Pocket of Dual Antagonist Almorexant to Human Orexin 1 and Orexin 2 Receptors: Comparison with the Selective OX1 Antagonist SB-674042 and the Selective OX2 Antagonist N- Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). Mol Pharmacol. 2010, 78, 81–93.
61) Gozzi, A.; Turrini, G.; Piccoli, L.; Massagrande, M.; Amantini, D.; Antolini, M.; Martinelli, P.; Cesari, N.; Montanari, D.; Tessari, M.; Corsi, M.; Bifone, A., Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS One 2011, 6, e16406.
62) Steiner, M. A.; Gatfield, J.; Brisbare-Roch, C.; Dietrich, H.; Treiber, A.; Jenck, F.; Boss, C., Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem 2013, 8, 898–903.
63) Johnson, P. L.; Truitt, W.; Fitz, S. D.; Minick, P. E.; Dietrich, A.; Sanghani, S.; Traskman-Bendz, L.; Goddard, A. W.; Brundin, L.; Shekhar, A., A key role for orexin in panic anxiety. Nat Med 2010, 16, 111–115.
64) Stump, C. A.; Cooke, A. J.; Bruno, J.; Cabalu, T. D.; Gotter, A. L.; Harell, C. M.; Kuduk, S. D.; McDonald, T. P.; O'Brien, J.; Renger, J. J.; Williams, P. D.; Winrow, C. J.; Coleman, P. J., Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology. Bioorg. Med. Chem. Lett. 2016, 26, 5809–5814.
65) Nagase, H.; Yamamoto, N.; Yata, M.; Ohrui, S.; Okada, T.; Saitoh, T.; Kutsumura, N.; Nagumo, Y.; Irukayama-Tomobe, Y.; Ishikawa, Y.; Ogawa, Y.; Hirayama, S.; Kuroda, D.; Watanabe, Y.; Gouda, H.; Yanagisawa, M., Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies. J. Med. Chem. 2017, 60, 1018– 1040.
66) Smart, D.; Sabido-David, C.; Brough, S. J.; Jewitt, F.; Johns, A.; Porter, R. A.; Jerman, J. C., SB- 334867-A: the first selective orexin-1 receptor antagonist. Br. J. Pharmacol. 2001, 132, 1179–1182.
67) McElhinny, C. J., Jr.; Lewin, A. H.; Mascarella, S. W.; Runyon, S.; Brieaddy, L.; Carroll, F. I., Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: possible confounding effects on in vivo and in vitro studies. Bioorg. Med. Chem. Lett. 2012, 22, 6661–6664.
68) Molecular docking simulation is used CDOCKER of Discovery Studio 2016 programa. The input receptor of the molecular docking simulation is OX1 R (PDB: 4zj8.pdb) and OX2 R (PDB: 4s0v.pdb). The OX1 R and OX2 R is added hydrogen atoms using Protenate 3D method of Molecular Operating Environment program (MOE)b. The hydrogens of OX1 R and OX2 R are optimized by molecular mechanics using Amber10 forcefield of MOE. The input site sphere of the molecular docking simulation is region of the suvorexant of the OX1 R and the OX2 R. The electrostatic potential surface is used a charge density obtained by solving the Poisson-Boltzmann equation of MOE. a) Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2016, San Diego: Dassault Systèmes, 2016. b) Molecular Operating Environment (MOE), 2015.10; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2016.
69) Rappas, M.; Ali, A. A. E.; Bennett, K. A.; Brown, J. D.; Bucknell, S. J.; Congreve, M.; Cooke, R. M.; Cseke, G.; de Graaf, C.; Doré, A. S.; Errey, J. C.; Jazayeri, A.; Marshall, F. H.; Mason, J. S.; Mould, R.; Patel, J. C.; Tehan, B. G.; Weir, M.; Christopher, J. A., Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. J. Med. Chem. 2020, 63, 1528–1543.
70) Skudlarek, J. W.; DiMarco, C. N.; Babaoglu, K.; Roecker, A. J.; Bruno, J. G.; Pausch, M. A.; O'Brien, J. A.; Cabalu, T. D.; Stevens, J.; Brunner, J.; Tannenbaum, P. L.; Wuelfing, W. P.; Garson, S. L.; Fox, S. V.; Savitz, A. T.; Harrell, C. M.; Gotter, A. L.; Winrow, C. J.; Renger, J. J.; Kuduk, S. D.; Coleman, P. J., Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists. Bioorg. Med. Chem. Lett. 2017, 27, 1364–1370.
71) Préville. C.; Bonaventure, P.; Koudriakova, T.; Lord, B.; Nepomuceno, D.; Rizzolio, M.; Mani, N.; Coe, K. J.; Ndifor, A.; Dugovic, C.; Dvorak, C. A.; Coate, H.; Pippel, D. J.; Fitzgerald, A.; Allison, B.; Lovenberg, T. W.; Carruthers, N. I.; Shireman, B. T., Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793. ACS Med. Chem. Lett. 2020, 11, 2002–2009.
72) Hellmann, J.; Drabek, M.; Yin, J.; Gunera, J.; Pröll, T.; Kraus, F.; Langmead, C. J.; Hübner, H.; Weikert, D.; Kolb, P.; Rosenbaum, D. M.; Gmeiner, P., Structure-based development of a subtype- selective orexin 1 receptor antagonist. Proc. Natl. Acad. Sci. U. S. A. 2020, 117, 18059–18067.
73) Caldirola, D.; Alciati, A.; Cuniberti, F.; Perna, G., Experimental Drugs for Panic Disorder: An Updated Systematic Review. J. Exp. Pharmacol. 2021, 13, 441–459.
74) Salvadore, G.; Bonaventure, P.; Shekhar, A.; Johnson, P. L.; Lord, B.; Shireman, B. T.; Lebold, T. P.; Nepomuceno, D.; Dugovic, C.; Brooks, S.; Zuiker, R.; Bleys, C.; Tatikola, K.; Remmerie, B.; Jacobs, G. E.; Schruers, K.; Moyer, J.; Nash, A.; Van Nueten, L. G. M.; Drevets, W. C., Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl. Psychiatry 2020, 10, 308.
75) David A. P.; Yanan Z., Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res. 1999, 1731, 145922.
論文の公開元へ
